Artificial intelligence-detected HER2 strong-positive tumor proportion predicts FISH positivity and treatment response in breast cancer
PLOS One · 06.07.2026 · 21 (7) · e0352979
DOI: 10.1371/journal.pone.0352979 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 06.07.2026. Verfasst von Seung Geun Song und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, In Situ Hybridization, Fluorescence, Artificial Intelligence. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Korea Medical Institute, Kyung Hee University.
Abstract (Originalsprache)
Human epidermal growth factor receptor 2 (HER2)-targeted therapies have revolutionized breast cancer treatment, necessitating standardized HER2 testing. However, current immunochemistry-based HER2 assessment faces challenges due to subjectivity and variability among observers, prompting the guidance of artificial intelligence (AI). We evaluated AI’s efficacy in HER2 status assessment and treatment response prediction, especially focusing on complete and intense circumferential HER2-positive (3+) tumor cells. An AI-powered HER2 analyzer (Lunit SCOPE HER2, Lunit Inc., Seoul, South Korea) and three pathologists independently assessed HER2 3 + tumor cell proportions from whole-slide images of 191 breast cancer cases from Kyung Hee University Hospital. Logistic regression and receiver operating characteristic (ROC) curves determined predictive accuracy. AI-detected 3 + tumor cell proportions strongly correlated with fluorescent in situ hybridization (FISH) positivity (area under ROC curve [AUC]: 0.783) and pathological complete response (pCR) rates (odds ratio [OR]: 1.003–1.052), outperforming pathologists’ assessments. Combining AI improved prediction accuracy of pathologists, with an AUC increased from 0.712–0.813 to 0.790–0.821 for predicting FISH positivity and median OR increased from 0.996–1.061 to 1.003–1.055 for predicting pCR. Overall, this preliminary study suggests that AI could enhance HER2 status determination and treatment response prediction, complementing traditional pathological evaluation of HER2 immunohistochemistry.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Lunit, Seoul, Republic of Korea.
- Department of Internal Medicine, Kyung Hee University College of Medicine, Seoul, Republic of Korea.
- Department of Pathology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Republic of Korea.
- Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Seung Geun Song, Taeyong Sim, Sangwon Shin, Minsun Jung
Förderung
- National Research Foundation of Korea
- Korea Medical Institute
- Kyung Hee University
Zitieren
APA
Song, S. G., Cho, S. I., Sim, T., Shin, S., Jung, W., Shin, J., Kim, S., Song, H., Pereira, S., Yoo, D., Baek, S. K., Na, K., Jung, M., & Kim, S. W. (2026). Artificial intelligence-detected HER2 strong-positive tumor proportion predicts FISH positivity and treatment response in breast cancer. PLOS One, 21(7), e0352979. https://doi.org/10.1371/journal.pone.0352979
Vancouver
Song SG, Cho SI, Sim T, Shin S, Jung W, Shin J, et al. Artificial intelligence-detected HER2 strong-positive tumor proportion predicts FISH positivity and treatment response in breast cancer. PLOS One. 2026;21(7):e0352979. doi:10.1371/journal.pone.0352979
BibTeX
@article{Song2026,
author = {Song, Seung Geun and Cho, Soo Ick and Sim, Taeyong and Shin, Sangwon and Jung, Wonkyung and Shin, Jisoo and Kim, Sukjun and Song, Heon and Pereira, Sérgio and Yoo, Donggeun and Baek, Sun Kyung and Na, Kiyong and Jung, Minsun and Kim, So-Woon},
title = {Artificial intelligence-detected HER2 strong-positive tumor proportion predicts FISH positivity and treatment response in breast cancer},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {7},
pages = {e0352979},
doi = {10.1371/journal.pone.0352979}
}
EUVIMED